"Designing Growth Strategies is in our DNA"
A bleeding disorder is a term collectively used for medical conditions where the blood is unable to form clot properly. Frequent nose bleeding, heavy menstrual bleeding, excessive bruising, and extended bleeding after vaccination or surgery are some of the symptoms associated with bleeding disorders. They can be acquired or congenital. Hemophilia A & B and Von Willebrand's disease are the most common types of bleeding disorders among people. Others include vitamin K deficiency, factor II, V, VII, X, or XII deficiencies.
According to the World Federation of Hemophilia (WFH), it was estimated that the number of people with bleeding disorders increased by 6.8% from 2016 to 2017 which is likely to upsurge the demand for the effective therapies to treat the various bleeding disorders and additionally new product launches by many key players are likely to boost the growth of bleeding disorders therapeutics market during the forecast period.
To gain extensive insights into the market, Request for Customization
In March 2019, Biotest AG received the for usage of reduced Haemoctin SDH volume by half for the treatment of hemophilia A.This reduction in the solvent volume enhanced the quality life of the patient, especially in small children suffering with hemophilia A by minimizing the duration of injection and exposing less stress on the veins of small children.
Certain factors anticipated to accelerate the growth of the bleeding disorders therapeutics market during the forecast period are the presence of potential pipeline candidates in R&D, growing prevalence of Hemophilia, and an increase in the demand for cost-effective treatment options for the treatment of various bleeding disorders.
However, increasing cost of the treatment unaffordable by low-middle income countries is likely to hamper the growth of bleeding disorders therapeutics market during the forecast period.
Some of the major companies that are present in the global Bleeding Disorders Therapeutics market are Grifols, S.A., CSL, Octapharma, Shire, Kedrion S.p.A, China Biologic Products Holdings, Inc., Bayer AG, Pfizer Inc., Novo Nordisk A/S, others.
· Plasma-Derived Coagulation Factor Concentrates
· Recombinant Coagulation Factor Concentrates
· Fibrin Sealants
· Hemophilia A
· Hemophilia B
· Von Willebrand Disease
By End Users
· Ambulatory Surgical Centres
· Specialty Clinics
· North America (U.S. and Canada)
· Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
· Latin America (Brazil, Mexico, and Rest of Latin America)
· Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)
Among product segmentation, the recombinant coagulation factor concentrates segment is anticipated to account for the largest share of global bleeding disorders therapeutics market during the forecast period owing to the growing usage of it as the most critical form of treatment for the Hemophilia A disease.
Geographically, the global bleeding disorders therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are likely to dominate the bleeding disorders therapeutics the market during the forecast period owing to the increase in the prevalence bleeding disorders and growing investments in research activities by many key players in the development of novel products. In the Asia Pacific region, China and India are expected to be the fast emerging markets due to the rising awareness by government organizations about the various bleeding disorders & available treatment options and increase in the development of healthcare infrastructures.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry